Antabio is a private biopharmaceutical company developing novel antibacterial resistance-breakers to treat drug-resistant infections in areas of highest unmet medical need. We are developing stand-alone inhibitors of bacterial metalloenzymes that can be combined with various antibiotics to restore their activity against the most critical pathogens. The company’s lead product is expected to enter the clinic in 2019 with a fast track to anticipated marketing approval by 2023. Antabio has built a best in class, international team of experts in the field to progress its pipeline. The Company is in the process of acquiring additional assets focused on Gram-negative antibiotic resistant therapies.
Antabio has built an international team of experts to understand and resolve the most urgent unmet medical needs of the antibacterial space. We are dedicated to developing a pipeline of novel antibacterial treatments to address infections caused by WHO’s priority pathogens and fill important gaps in the antibiotic armamentarium
HISTORY & KEY FACTS ABOUT ANTABIO
Antabio’s metallo ß-lactamases inhibitor programme (MBLi) receives € 4.7 Million Award from the Wellcome Trust
Antabio receives a Wellcome Trust Seeding Drug Discovery Award of €4.7m over 3 years to fund the development of a novel, safe and efficacious inhibitor of bacterial metallo ß-lactamases, from leads to preclinical candidate nomination. The project team was led by Principal Investigator Dr. Marc Lemonnier CEO of Antabio.
ANTABIO receives €4 Million to develop new drugs to treat chronic infections in Cystic Fibrosis patients.
This second Seeding Drug Discovery funding awarded to Antabio by the Wellcome Trust in as many years was used to support the discovery of a first-in-class inhibitor of Pseudomonas virulence to be co-administered with standard-of-care antibiotics for the long-term management of chronic respiratory infections in CF patients.
ANTABIO is awarded up to $8.9M from CARB-X to accelerate the development of its new treatment for chronic infections in Cystic Fibrosis patients
Antabio is awarded up to $8.9 million non-dilutive funding from CARB-X, the world’s largest public-private partnership devoted to antibacterial R&D. Antabio was selected by CARB-X from a group of 368 applicants worldwide and is part of the first cohort that includes companies from Continental Europe. The award provides funding to accelerate the development up to completion of Phase 1 clinical trials of Antabio’s PEI program (Pseudomonas Elastase Inhibitors) that seeks to develop a novel small molecule drug for the treatment of chronic Pseudomonas infections in Cystic Fibrosis patients.
ANTABIO raises € 7.3M Series A Financing to Develop Novel Treatments against Drug-Resistant Gram-negative infections
Antabio completes a €7.3M series A financing with subscriptions from investment funds iXO Private Equity, IRDI SORIDEC Gestion, Galia Gestion and from the company’s historical investors including former President of OM Pharma Christophe Ricard.